Case series comparing outcomes in clinically diagnosed versus pathologically proven non-small cell lung cancer (NSCLC) treated with Stereotactic Ablative Body Radiotherapy
| Author | Number of patients | Follow-up period | Outcome | Potential confounding factors |
|---|---|---|---|---|
| Takeda et al262 | 58 CDLC vs 115 pathologically proven NSCLC | 20.2 Months CDLC (range 6–59) vs 21.2 months NSCLC (range 6–64) | 3 Year local control 80% vs 87% (p=0.73) and OS 54% vs 57% (p=0.48) | Fewer operable tumours in CDLC group |
| Verstegen et al263 | 382 CDLC vs 209 pathologically proven NSCLC | Not supplied | 3 Year local control 91% vs 90% (p=0.98) and OS 54% vs 55% (p=0.99) | Lower FEV1 and smaller tumour size in CDLC group |
| Haidar et al264 | 23 CDLC vs 32 pathologically proven NSCLC | 24.2 Months CDLC (range 2–65) vs 25.8 months NSCLC (range 4–53) | Local control at last follow-up 91% vs 94% (p=NS) and actuarial 2 year OS 65% vs 64% (p=NS) | Smaller tumour size in CDLC group |
| Stephans et al265 | 33 CDLC vs 61 pathologically proven NSCLC | 15.3 Months (range 2–48) for whole cohort | No significant difference in OS (p=0.37)—actual rates not supplied | Probably multiple, but patient characteristics not reported by CDLC/NSCLC |
CDLC, clinically diagnosed lung cancer; FEV1, forced expiratory volume in one second; NSCLC, non-small cell lung cancer; OS, overall survival.